Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Clin Cancer Res. 2011 Jun 14;17(15):5123–5131. doi: 10.1158/1078-0432.CCR-11-0682

Fig. 1.

Fig. 1

Percentage of HIF-1α–positive cells in samples from baseline and post-treametment tumor bisopises from seven evaluable patients, reported per patient (A) and as mean ± SD (B). Immunohistochemistry staining for HIF-1α shown for patient 4 (breast cancer) at baseline and after two cycles of topotecan (C).

HHS Vulnerability Disclosure